港股異動丨復宏漢霖升近9% 股價續創歷史新高 較年內低點已反彈超4.6倍!
復宏漢霖(2696.HK)午後一度升8.8%至85.95港元,股價續創歷史新高,市值達466億港元,年內已累升超2.6倍,較1月23日盤中觸及的年內低點(15.2港元)已累升465.46%。個股方面,2025年世界肺癌大會(WCLC)官網日前公佈入選摘要名單,復宏漢霖在肺癌領域的10項研究成功入選多個重要專場,包括4項口頭報吿及2項壁報導覽,覆蓋NSCLC、SCLC等多個亞型一線治療領域,顯示公司在全球學術舞台的影響力持續提升。花旗認為復宏漢霖即將在世界肺癌大會(WCLC)公佈HLX43的最新數據,將進一步揭示其在非小細胞肺癌(NSCLC)治療的潛力。該行估算HLX43的經風險調整銷售高峯可達約23億美元,如果在NSCLC及其他適應症方面取得更多數據,仍有上行空間。該行將復宏漢霖的目標價由35港元大幅上調至95港元,評級由“中性”上調至“買入”。行業方面,中共中央政治局常委、國務院總理李強8月20日在北京調研生物醫藥產業發展情況。他強調,要加大高質量科技供給和政策支持,充分發揮企業創新主體作用,着力推動生物醫藥產業提質升級。有分析認為,這預示着國家層面將持續並加大對該行業的政策扶持和資源投入。這並非李強總理首次提及此事,但持續的高層發聲,尤其是在當前經濟背景下,傳遞出了非常強烈和積極的信號。(格隆匯)

Follow us
Find us on
Facebook,
Twitter ,
Instagram, and
YouTube or frequent updates on all things investing.Have a financial topic you would like to discuss? Head over to the
uSMART Community to share your thoughts and insights about the market! Click the picture below to download and explore uSMART app!

Disclaimers
uSmart Securities Limited (“uSmart”) is based on its internal research and public third party information in preparation of this article. Although uSmart uses its best endeavours to ensure the content of this article is accurate, uSmart does not guarantee the accuracy, timeliness or completeness of the information of this article and is not responsible for any views/opinions/comments in this article. Opinions, forecasts and estimations reflect uSmart’s assessment as of the date of this article and are subject to change. uSmart has no obligation to notify you or anyone of any such changes. You must make independent analysis and judgment on any matters involved in this article. uSmart and any directors, officers, employees or agents of uSmart will not be liable for any loss or damage suffered by any person in reliance on any representation or omission in the content of this article. The content of the article is for reference only and does not constitute any offer, solicitation, recommendation, opinion or guarantee of any securities, virtual assets, financial products or instruments. Regulatory authorities may restrict the trading of virtual asset-related ETFs to only investors who meet specified requirements. Any calculations or images in the article are for illustrative purposes only.
Investment involves risks and the value and income from securities may rise or fall. Past performance is not indicative of future performance. Please carefully consider your personal risk tolerance, and consult independent professional advice if necessary.